Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Teva
UBS
Moodys
Dow
Fish and Richardson
US Department of Justice
Queensland Health
McKesson
Federal Trade Commission
Citi

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,859,006

« Back to Dashboard

Summary for Patent: 5,859,006
Title: Tetracyclic derivatives; process of preparation and use
Abstract:A compound of formula (I) ##STR1## and salts and solvates thereof, in which: R.sup.0 represents hydrogen, halogen or C.sub.1-6 alkyl; R.sup.1 represents hydrogen, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, haloC.sub.1-6 alkyl, C.sub.3-8 cycloalkyl, C.sub.3-8 cycloalkylC.sub.1-3 alkyl, arylC.sub.1-3 alkyl or heteroarylC.sub.1-3 alkyl; R.sup.2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan and pyridine or an optionally substituted bicyclic ring ##STR2## attached to the rest of the molecule via one of the benzene ring carbon atoms and wherein the fused ring A is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur and nitrogen; and R.sup.3 represents hydrogen or C.sub.1-3 alkyl, or R.sup.1 and R.sup.3 together represent a 3- or 4-membered alkyl or alkenyl chain. A compound of formula (I) is a potent and selective inhibitor of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase (cGMP specific PDE) having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of cardiovascular disorders.
Inventor(s): Daugan; Alain Claude-Marie (Les Ulis, FR)
Assignee: ICOS Corporation (Bothell, WA)
Application Number:08/669,389
Patent Claim Types:
see list of patent claims
Compound; Use; Composition; Process;

Drugs Protected by US Patent 5,859,006

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eli Lilly Co ADCIRCA tadalafil TABLET;ORAL 022332-001 May 22, 2009 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y TREATMENT OF PULMONARY HYPERTENSION ➤ Subscribe
Lilly CIALIS tadalafil TABLET;ORAL 021368-004 Jan 7, 2008 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Lilly CIALIS tadalafil TABLET;ORAL 021368-001 Nov 21, 2003 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Lilly CIALIS tadalafil TABLET;ORAL 021368-002 Nov 21, 2003 RX Yes No ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Lilly CIALIS tadalafil TABLET;ORAL 021368-003 Nov 21, 2003 RX Yes Yes ➤ Subscribe ➤ Subscribe Y Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 5,859,006

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9401090Jan 21, 1994
PCT Information
PCT FiledJanuary 19, 1995PCT Application Number:PCT/EP95/00183
PCT Publication Date:July 27, 1995PCT Publication Number: WO95/19978

Non-Orange Book US Patents Family Members for Patent 5,859,006

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,143,746 Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use ➤ Subscribe
5,981,527 Cyclic GMP-specific phosphodiesterase inhibitors ➤ Subscribe
6,784,179 Tetracyclic derivatives, process of preparation and use ➤ Subscribe
6,025,494 Tetracyclic derivatives, process of preparation and use ➤ Subscribe
6,369,059 Tetracyclic derivatives, process of preparation and use ➤ Subscribe
6,140,329 Use of cGMP-phosphodiesterase inhibitors in methods and compositions to treat impotence ➤ Subscribe
6,127,542 Tetracyclic derivatives, process of preparation and use ➤ Subscribe
6,608,065 Use of cGMP phosphodiesterase inhibitors in methods to treat female sexual dysfunction ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,859,006

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Israel 112384 ➤ Subscribe
Brazil 9609758 ➤ Subscribe
Brazil 9913824 ➤ Subscribe
Canada 2181377 ➤ Subscribe
Canada 2226761 ➤ Subscribe
Canada 2226784 ➤ Subscribe
Canada 2340636 ➤ Subscribe
China 1143963 ➤ Subscribe
China 1045777 ➤ Subscribe
China 1195349 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Medtronic
Accenture
QuintilesIMS
Farmers Insurance
Merck
Moodys
Baxter
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot